Tag: BioMarin Pharmaceutical Inc.

BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS

Second Quarter 2025 Total Revenues of $825 million (+16% Y/Y and +17% at Constant Currency Y/Y) Second Quarter 2025 GAAP Diluted Earnings Per Share (EPS)...

BioMarin Announces Appointment of Ian T. Clark to Board of Directors

SAN RAFAEL, Calif., Aug. 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Ian T. Clark to the...

- A word from our sponsors -

HomeTagsBioMarin Pharmaceutical Inc.

Crypto Market News: AlphaPepe Presale Advances CoinGecko Listing as XRP Price Prediction Hits $7.00

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Toobit Launches Prediction Market for Event-Based Trading

Tag: BioMarin Pharmaceutical Inc.

BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS

BioMarin Announces Appointment of Ian T. Clark to Board of Directors

Explore

Press Releases

News & Opinion

Living

Others

Follow us